Compare Tidewater Inc (TDW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Tango Therapeutics Inc. — how do they compare? Tidewater Inc trades at $83.01 (market cap $4.12B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tidewater Inc and Tango Therapeutics Inc. are close in size by market cap, and Tidewater Inc is more actively traded (718,273 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 27 Days and Tango Therapeutics Inc. for 0 Days on average.
| TDW | TNGX | |
|---|---|---|
Market Cap | $4.12B | $3.74B |
Volume | 718,273 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $100.61 | $32.90 |
52-Week Low | $47.29 | $7.50 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $4.16B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net income margin and 19.49% ROE, though recent quarterly EPS missed expectations. The acquisition of Wilson Sons Ultratug (Business Wire, 2026-08-31) expands its offshore services footprint. Analyst consensus price target is $105.50, implying potential upside from current levels.
The outlook is cautiously optimistic, supported by solid cash flow and institutional interest, but risks include earnings volatility and competitive pressures. Revenue declined to $1.3B in 2026 from $1.4B in 2025, and profit margins compressed, requiring monitoring of operational execution amid energy market fluctuations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
